Only a day after Novartis said it was looking at offering its manufacturing network to the global COVID-19 fight, the company is joining forces with Pfizer and BioNTech to help produce mRNA vaccines. It’s the latest example of an unlikely Big Pharma partnership spurred by the urgent need to defeat the pandemic.
Novartis inked an initial agreement with BioNTech to allow the mRNA biotech use of Novartis’ facility in Stein, Switzerland. The production will start in the second quarter, and the partners expect dose deliveries to begin in the third quarter.
The Pfizer/BioNTech shot is one of only a few that have been approved in countries around the world, and in the early stages of the rollout, demand has greatly outstripped supply. Pfizer and BioNTech have been working to scale up their manufacturing network to deliver 2 billion doses this year, but the effort led to a temporary supply disruption in Europe earlier this month.
Under the Novartis pact, the Swiss drugmaker will receive bulk mRNA active ingredient from BioNTech and fill it into vials. The company will then ship those vials back to BioNTech for global distribution.
As the companies gear up for the work, Novartis is also in “advanced discussions” with multiple other companies involved in COVID-19 vaccines and therapeutics.
“Novartis has been mobilizing on multiple fronts to support the global pandemic response,” Novartis Technical Operations head Steffen Lang said in a statement, adding, “We expect this to be the first of a number of such agreements.”
For the Pfizer/BioNTech team, it’s their second manufacturing tie-up with a big pharma this week. Early in the week, Sanofi said it would produce 100 million shots of the mRNA vaccine for delivery in 2021.
Amid the pandemic, drug companies that are typically rivals have joined forces to collaborate on research or manufacturing for drugs and vaccines. Aside from Sanofi’s manufacturing partnership with Pfizer and BioNTech, the company joined forces with vaccine rival GlaxoSmithKline earlier in the pandemic to advance an adjuvanted shot. The companies remain in midstage testing.
On the manufacturing side, Regeneron and Roche have teamed up to boost antibody production, as have Eli Lilly and Amgen.
by Eric Sagonowsky
Source: fiercepharma.com
Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.
